4BASEBIO PLC

• ◆

  Material uncertainty over going concern

  We draw attention to note 2 in the financial statements, which indicates that there is uncertainty over the revenue forecast and, if required, over the timing and quantum of an additional fund raise... these events or conditions... indicate that a material uncertainty exists that may cast significant doubt on the Group and company's ability to continue as a going concern. Our opinion is not modified in respect of this matter.

• ·

  Going-concern uncertainty disclosed

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers

Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Margin ratios are hidden where reported turnover is too small relative to profit to yield a meaningful figure — typical of holding companies whose income is mostly subsidiary dividends rather than trading revenue. Sector-distribution context coming next.

Accounting basis

UK-adopted IFRS

Reporting scope

Consolidated group

Auditor

Crowe U.K. LLP

Audit opinion

Unqualified (clean)

Going concern

Material uncertainty disclosed

“We draw attention to note 2 in the financial statements, which indicates that there is uncertainty over the revenue forecast and, if required, over the timing and quantum of an additional fund raise... these events or conditions... indicate that a material uncertainty exists that may cast significant doubt on the Group and company's ability to continue as a going concern. Our opinion is not modified in respect of this matter.”

Group structure

1. 4BASEBIO PLC · parent
   1. 4basebio S.L.U. 100% · Spain · R&D and product development
   2. 4basebio UK Limited 100% · UK · DNA manufacture and commercial operations
   3. 4basebio Discovery Limited 100% · UK · R&D and product development
   4. 4basebio Inc. 100% · USA · US commercial operations

Significant events

• “On 10 February 2026, the Company announced that Dr Amy Walker, previously Chief Operating Officer, had been appointed Chief Executive Officer with immediate effect, succeeding Dr Heikki Lanckriet, the Founder, who stepped down as Chief Executive Officer after six years in the role.”
• “On 3 March 2026, the Company announced that it had entered into a lease for a new innovation hub and manufacturing facility in Cambridge, UK, supporting growing demand for research and high-quality grade synthetic DNA manufacturing.”
• “On 27 April 2026, the Group received a countersigned drawdown notice in respect of a €7 million facility from 2Invest AG. Funds were received by the Group on 30 April 2026. The facility provides additional liquidity headroom for the Group over the going concern assessment period.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

11

last 12 months

Capital events

3

last 24 months

Officers appointed

0

last 12 months

Officers resigned

2

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.